{
    "doi": "https://doi.org/10.1182/blood.V122.21.2812.2812",
    "article_title": "Azacitidine Alone Or The Combination With Valproic Acid As a Bridge Therapy For Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes Before Transplantation ",
    "article_date": "November 15, 2013",
    "session_type": "633. Myelodysplastic Syndromes: Poster II",
    "abstract_text": "Introduction Intensive chemotherapy (IC) followed by allogeneic stem cell transplantation (AlloSCT) is standard of care for intermediate and high-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). However, morbidity and lack of response are common with IC. Retrospective data have shown similar outcomes with azacitidine (AZA) when compared to IC. Moreover, the combination of AZA with other epigenetic modifiers such as HDAC inhibitors seems to improve quality of responses. Aim Evaluate response, toxicity and feasibility of AlloSCT after AZA alone or the combination with valproic acid (VPA) as a bridge strategy in MDS and AML. Patients Nineteen consecutive patients (pts) receiving azacitidine alone (n=11) or in combination with valproic acid (VPA) (n=8) were analyzed. Median age of the cohort was 57 years (18-67). Diagnosis by WHO classification included: RAEB-2 (n=10/19; 52.6%), RAEB-1 (n=2; 10.5%), RCMD (n=2; 10.5%) and AML (n=5; 26.3%). Four out of 5 AML pts had bone marrow blast count >30% at diagnosis. In MDS patients, according to International Prognostic Scoring System (IPSS): 1 intermediate-1 (7%), 3 intermediate-2 (21.5%) and 10 high-risk (71.5%) and by IPSS-revised (IPSS-R): 1 intermediate (7%), 4 high (29%) and 9 very high (64%). Regarding karyotype, in MDS: 5 good (35.7%), 2 intermediate (14.3%), 6 poor (43%) and 1 insufficient metaphases (7%) whereas in AML Patients 1 intermediate (20%) and 4 adverse (80%). Eleven out of 19 pts (58%) received AZA as frontline therapy. The remaining 8 pts experienced disease relapse after intensive chemotherapy (IC) or had primary refractory AML, and subsequently received AZA plus VPA as salvage therapy. Median courses of previous IC were 2 (1-4). For pts receiving AZA/VPA, median bone marrow blast % and leukocyte were 31% (2-60) and 1.9x10e 9 /L (0.3-4.2) when therapy started. Most of these pts had refractory or relapsed disease (n=6/8; 75%) with 4 pts displaying poor karyotype. Treatment schema was AZA (75 mg/m 2 , 7d/4w) and VPA (20-25 mg/kg/d, 10 days). Results At analysis, 17/19 pts are evaluable for response. Median courses of AZA: 5 (2-53). Overall response (ORR) at 4 courses: 59% (CR=4/17; 23.5%, CRm=5/17; 29.5% and PR=1/17; 6%). For pts receiving AZA/VPA ( Table 1 , n=8), ORR: 83% (CR=1/6; 17% and CRm=4/6, 66%) in 6 evaluable pts. Median courses to response were 2. Among pts achieving CR/CRm/PR/SD at 4 courses (n=12), 2 pts lost response prior to AlloSCT. Most frequent toxicity was hematological (58% grade 3-4) with no treatment related mortality attributable to AZA/VPA. Eleven out of 19 pts (58%) received AlloSCT (matched related=5, matched unrelated=5, haploidentical=1). Causes for not proceeding to AlloSCT: Disease progression (n=4; 50%), infection (n=1; 12.5%), pending evaluation after 2 courses (n=2; 25%) and 1 pt (12.5%) scheduled for matched unrelated AlloSCT. Conditioning regimen: Reduced intensity (9/11) and myeloablative (2/11). Tacrolimus/sirolimus (50%) and cyclosporine/MMF (40%) as GVHD prophylaxis. With a median follow-up of 4 months after AlloSCT (1-26), only 1 pt developed acute GVHD, 1 had early relapse postransplant and 9 patients continue in CR at last follow up. Table 1 Patients treated with the combination of AZA/VPA  Diagnosis . Leukocytes (x10e 9 /L) . Karyotype . Frontline Previous IC . Response a . AML 1.82 45,XX,-7[13] IC 1  CR RAEB-2 2.02 46,XY[20] IC 2  CRm RAEB-2 1.02 IM IC 1  CRm AML 3.1 46,XX,ins(9;?)(p10;?)[20] IC 1  Failure AML 0.3 46,XX[20] IC 1  CRm AML 4.3 40-42,X,-Y,t(2;11)(p23;q21),t(3;16)(q25;p13), i(5)(p10),-7,-13,-18,der(?)t(Y;18)(q12;?),-20,der(?)t(Y;21)(q12;?)[cp 20] Frontline NA AML 3.2 46,XX,t(3;3)(q21;q26.2)[5]/46,XX[6] IC 1  CRm RAEB-1 1.3 IM* Frontline NA Diagnosis . Leukocytes (x10e 9 /L) . Karyotype . Frontline Previous IC . Response a . AML 1.82 45,XX,-7[13] IC 1  CR RAEB-2 2.02 46,XY[20] IC 2  CRm RAEB-2 1.02 IM IC 1  CRm AML 3.1 46,XX,ins(9;?)(p10;?)[20] IC 1  Failure AML 0.3 46,XX[20] IC 1  CRm AML 4.3 40-42,X,-Y,t(2;11)(p23;q21),t(3;16)(q25;p13), i(5)(p10),-7,-13,-18,der(?)t(Y;18)(q12;?),-20,der(?)t(Y;21)(q12;?)[cp 20] Frontline NA AML 3.2 46,XX,t(3;3)(q21;q26.2)[5]/46,XX[6] IC 1  CRm RAEB-1 1.3 IM* Frontline NA View Large Conclusions AZA alone and particularly the combination AZA/VPA prior to AlloSCT is a well-tolerated and highly effective schema even in pts with poor prognostic features and refractory to prior IC. Adequate selection of pts (leukocyte <10x10e 9 /L) and larger prospective studies are needed to assess the role of this strategy. AML; Acute myeloid leukemia, RAEB-2; Refractory anemia with excess blasts type 2, RAEB-1; Refractory anemia with excess blasts type 1, IM; Insufficient metaphases, IC; Intensive chemotherapy, CR; Complete response, CRm; marrow CR, NA; Not assessable (pending bone marrow evaluation). 1 Refractory to IC. 2 Relapsed after IC. a Bone marrow evaluation after 2 and 4 courses of therapy Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "azacitidine",
        "leukemia, myelocytic, acute",
        "myelodysplastic syndrome",
        "transplantation",
        "valproic acid",
        "brachial plexus neuritis",
        "refractory anemia with excess blasts",
        "chemotherapy regimen",
        "karyotype determination procedure",
        "prostatic hypertrophy risk score"
    ],
    "author_names": [
        "Cristina Calder\u00f3n Cabrera",
        "Jose F Falantes, MD",
        "Marina G\u00f3mez",
        "Roc\u00edo Parody, MD, PhD",
        "Francisco J M\u00e1rquez Malaver",
        "Mar\u00eda L Martino",
        "Jos\u00e9 Gonz\u00e1lez",
        "Isabel Montero",
        "Ildefonso Espigado",
        "Jose Antonio P\u00e9rez-Sim\u00f3n"
    ],
    "author_dict_list": [
        {
            "author_name": "Cristina Calder\u00f3n Cabrera",
            "author_affiliations": [
                "UGC Hematolog\u00eda y Hemoterapia. Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Jose F Falantes, MD",
            "author_affiliations": [
                "Instituto de Biomedicina de Sevilla (IBIS) Hospital Universitario Virgen del Roc\u00edo/CSIC/Universidad de Sevilla, Seville, Spain"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marina G\u00f3mez",
            "author_affiliations": [
                "UGC Hematolog\u00eda y Hemoterapia. Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Roc\u00edo Parody, MD, PhD",
            "author_affiliations": [
                "UGC Hematolog\u00eda y Hemoterapia. Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francisco J M\u00e1rquez Malaver",
            "author_affiliations": [
                "UGC Hematolog\u00eda y Hemoterapia. Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mar\u00eda L Martino",
            "author_affiliations": [
                "UGC Hematolog\u00eda y Hemoterapia. Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jos\u00e9 Gonz\u00e1lez",
            "author_affiliations": [
                "UGC Hematolog\u00eda y Hemoterapia. Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Isabel Montero",
            "author_affiliations": [
                "UGC Hematolog\u00eda y Hemoterapia. Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ildefonso Espigado",
            "author_affiliations": [
                "UGC Hematolog\u00eda y Hemoterapia. Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jose Antonio P\u00e9rez-Sim\u00f3n",
            "author_affiliations": [
                "UGC Hematolog\u00eda y Hemoterapia. Hospital Universitario Virgen del Roc\u00edo. Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-28T03:54:11",
    "is_scraped": "1"
}